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Abstract
Background: The necessity of antibiotic prophylaxis for postoperative urinary tract infections (UTIs) after
transurethral resection of bladder tumours is controversial. This potentially leads to the overuse of antibiotic
prophylaxis and rising antimicrobial resistance rates. The objective of this systematic review and meta-analysis is to
compare the impact of different antimicrobial prophylaxis schemes versus placebo on the prevention of
postoperative UTI and asymptomatic bacteriuria.
Methods: We designed and registered a study protocol for a systematic review and meta-analysis of randomized
controlled trials and non-randomized (e.g. cohort, case-control) studies examining any form of antibiotic prophylaxis
in patients with transurethral resection of bladder tumours. Literature searches will be conducted in several
electronic databases (from inception onwards), including MEDLINE (Ovid), EMBASE (Ovid), and the Cochrane Central
Register of Controlled Trials (CENTRAL). Grey literature will be identified through searching conference abstracts. The
primary outcome will be postoperative urinary tract infections. The secondary outcome will be asymptomatic
bacteriuria. Two reviewers will independently screen all citations, full-text articles, and abstract data. Potential
conflicts will be resolved through discussion. The study methodological quality (or bias) will be appraised using
appropriate tools (e.g. Risk of Bias 2.0 tool and Newcastle-Ottawa Scale). If feasible, we will conduct random-effects
meta-analysis of outcome data. Additional analyses will be conducted to explore the potential sources of
heterogeneity (e.g. study design, publication year, the setting of the study, and antibiotics regimen).
We will also search, identify, and discuss potential risk factors for urinary tract infections following transurethral
resection of bladder tumours. This may serve as basis for a scoping review.
Discussion: In times of rising antimicrobial resistance rates, sound evidence on the necessity of antibiotic
prophylaxis is essential for implementation into guideline recommendations and for decision-making in clinical
practice.
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Background
Bladder cancer is the most common malignancy of the
male and female urinary tract system [1]. For primary
diagnostics of bladder cancer, international guidelines
recommend transurethral resection of suspicious lesions
to obtain histology for a final exclusion of malignancy
and as a treatment option for non-muscle invasive blad-
der cancer [2]. According to the World Health
Organization, transurethral resection of bladder tumours
(TURB) is classified as a clean-contaminated wound pro-
cedure [3]. In general, in clean-contaminated proce-
dures, perioperative antibiotic prophylaxis (AP) is
recommended to prevent postoperative urinary tract in-
fections (UTIs) [4].
Nevertheless, in contrast to transurethral resection of
the prostate (TURP) [5, 6], UTI rates are lower following
TURB, and there appears to be little evidence for any
benefit of AP. A lack of consensus was demonstrated in
a recently published review that investigated the guide-
lines of the American Urological Association (AUA) and
the Canadian (CAU), European (EAU), and Japanese
(JAU) Associations of Urology [7]: The AUA considers
TURB along with TURP and consequently AP should be
applied to all patients, whereas the CAU groups TURB
with cystoscopy and recommends AP only in high-risk
patients. JAU guidelines recommend AP for TURB based
on data for other transurethral procedures but state that
low-risk cases without preoperative UTI can be consid-
ered to require no AP. EAU guidelines suggest assessing
risk factors for postoperative infections to determine the
use of AP. However, a closer definition of these risk fac-
tors is missing in the EAU guidelines.
The EAU recommendations are mainly based on one
review of randomized controlled trials (RCTs), which in-
cluded only two studies (n = 152) that compared AP to
placebo [8]. Both studies are from the 1980s and found a
nonsignificant decrease in the incidence of post-TURB
bacteriuria with the use of AP compared to placebo
(24.1% vs. 9.4% and 17% vs. 4.5%) and a 0% incidence of
symptomatic UTIs in both groups. It was concluded that
there is moderate- to low-grade evidence suggesting that
AP is not necessary for TURB [8].
The heterogeneity in the recommendations underline
that there is no consensus regarding the use of AP in
the prevention of UTI after TURB in international
guidelines. Nonetheless, application of AP after TURB
should be carefully considered as unnecessary antibiotics
increase the risk for emergence of multiresistant patho-
gens. Another complication comes from the lack of in-
formation in the guidelines on risk factors for UTI after
TURB, which challenges the implementation of recom-
mendations given for, e.g. “high-risk patients” only. Fur-
thermore, while risk factors for postoperative UTI after
transurethral surgery in general have been identified (see
e.g. [9]), risk factors for UTI specifically after TURB have
so far not been put together in a comprehensive way.
Taken together, the level of evidence for the necessity
of AP for postoperative UTIs following TURB remains
insufficiently documented. Moreover, even though con-
sideration of risk factors is recommended, only little is
known about risk factors for UTI after TURB.
The aims of this systematic review and meta-analysis
are to compare the impact of AP schemes vs. placebo in
patients undergoing TURB with the primary outcome of
symptomatic UTI and asymptomatic bacteriuria (ABU)
secondary.
Beyond the systematic review, we will explore and de-
scribe potential risk factors for UTIs following TURB as
basis for future research.
Methods
The present protocol has been registered within the PROS-
PERO database (registration number CRD42019131733)
and is reported in accordance with the reporting guidance
provided in the “Preferred Reporting Items for Systematic
Reviews and Meta-Analyses Protocols (PRISMA-P)” state-
ment (Additional file 1: Table S1) [10]. The planned sys-
tematic review and meta-analysis will be conducted in
accordance with the “Centre for Reviews and Dissemin-
ation (CRD)” guidelines [11].
Eligibility criteria
Studies will be included according to the following cri-
teria: participants, study design(s), intervention, compar-
ators and outcome(s) of interest. These criteria are:
Participants: We will include studies investigating pa-
tients ≥18 years (regardless of sex and age) undergoing
TURB. Study design: Eligible studies will be RCTs and
non-randomized (e.g. observational) studies, including
cohort studies and case-control studies. We will exclude
case reports, case series, and single-arm cohort studies.
Interventions and comparators: We will include any
scheme of AP (i.e. any duration varying from a single-
dose AP to several days, any oral or intravenous
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antibiotic substance eligible for the treatment or prophy-
laxis of UTI) vs. placebo (or no AP) and that report at
least one pertinent outcome in patients undergoing
TURB. Non-antibiotic prophylactic schemes are not eli-
gible (e.g. bladder instillations with antibiotics or hyalur-
onic acid/chondroitin sulphate, D-mannose,
immunoactive prophylaxis). Outcomes of interest: The
primary outcome will be postoperative symptomatic UTI
defined as symptoms including flank pain, urgency, fre-
quency, suprapubic pain, fever, and antimicrobial con-
firmation of bacteriuria (≥ 105 colony-forming units)
according to the definition of the Centers for Disease
Control and Prevention or as clinical diagnosis of cyst-
itis, pyelonephritis, prostatitis, and urosepsis. The sec-
ondary outcome will be ABU (≥ 105 colony-forming
units). The outcomes have to occur until 60 days follow-
ing the intervention.
For the exploration of potential risk factors for UTIs
following TURB, we will include any studies (RCTs and
non-randomized (e.g. observational) studies) that investi-
gate risk factors for UTIs (defined as described above) in
patients ≥ 18 years (regardless of sex and age) undergo-
ing TURB independent of the AP scheme. Examples of
risk factors for UTIs after TURB, which we anticipate to
find based on the knowledge from studies on risk factors
in lower urinary tract surgeries are health status, dur-
ation of catheterization, and duration of operation [9].
Search strategy for identifying relevant studies
Two information specialists (H.E. and C.A.-H.) will de-
velop the search strategies. The strategy for the system-
atic review (referred to as the “systematic search”) is
concerned with AP in TURB. Text words (synonyms
and word variations) and database-specific subject head-
ings for TURB and AP will be used. We will search the
electronic databases MEDLINE (Ovid) Embase (Ovid),
and the Cochrane Central Register of Controlled (CEN-
TRAL) from inception onwards (see draft search in Add-
itional file 2).
The strategy for the exploration of potential risk fac-
tors (referred to as “exploratory search”) will be con-
cerned with the identification and gathering of risk
factors for UTI after TURB. It will be based on free-text
synonyms and MeSH terms for TURB and UTIs and
conducted in MEDLINE (see draft search in Additional
file 3). To find additional references, we will also look
out for potential risk factors while screening the results
of the systematic search. The following supplementary
search techniques apply to both the systematic review
and the risk factors.
To identify additional conference abstracts, the ab-
stracts of the Annual EAU Congresses 2016–2019 will
be hand-searched in the European Urology Supplements
on ScienceDirect. To identify possible additional studies
that escape our electronic database searches, we will
screen the bibliographic references of all included arti-
cles as well as the citations of those that are indexed in
Scopus or the Web of Science.
Selection of studies for inclusion in the review
All retrieved references will be exported to Endnote X9
(Endnote Version X9.1.1, Clarivate Analytics, 2019). Du-
plicates will be removed using EndNote X9. Two re-
viewers (K.B. and L.M.S.) will screen the references
based on their titles and abstracts. All potentially rele-
vant references will be retrieved in full-text and inde-
pendently assessed by two reviewers (K.B. and L.M.S.).
Any disagreements over eligibility will be resolved by
consensus. Where necessary, a third review author (H.-
H. S.) will make a final judgement. This applies to both
the systematic and the exploratory search.
Risk of bias assessment
The Risk of Bias 2.0 (RoB.2.0) tool will be used to assess
the risk of bias in RCTs [12] and the Newcastle-Ottawa
Scale for non-randomized studies [13] included in the
systematic review. Assessments will be carried out inde-
pendently by two reviewers (K.B. and S.U.S.) at study-
level, with discrepancies being discussed with a third re-
viewer (H.-H.S.) to reach a consensus.
We will not assess risk of bias for studies that are only
included for the exploration of potential risk factors.
Data extraction and management
Data for the systematic review will be extracted and en-
tered into a pre-defined and piloted Microsoft Excel
database (Version 16.23, Microsoft Excel, 2019). Data
will be extracted by one reviewer (K.B.) and independ-
ently checked by a second reviewer (L.M.S.). Discrepan-
cies will be identified and resolved through discussion
(with a third author where necessary, S.U.S.). Data items
to be extracted will include the name of the first author,
year of publication, study location, setting, and study de-
sign. Furthermore, the number of participants in each
group, participant demographics (e.g. age, gender), any
reported confounding factors, definition of AP (e.g. re-
gime, duration), control intervention (i.e. including pla-
cebo, no treatment, standard of care, and other active
treatments), definition of UTI, number of symptomatic
UTI or ABU events per group, assessment of risk factors
for UTI, and duration of follow-up are information re-
quired for risk of bias assessments.
For the exploration of risk factors, we aim to extract
any reported risk factors for UTI after TURB as well as
the respective statistical methods that were used to iden-
tify them.
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Data synthesis
We will perform a meta-analysis to assess the impact of
AP on symptomatic UTI as a primary outcome. Using
the data extracted from each paper (e.g., study design,
design characteristics, author, year, quality of the study),
we will build the evidence table(s) of an overall descrip-
tion of included studies to explore possible heterogeneity
descriptively. The random-effects model will be used
then to account for potential statistical heterogeneity,
reporting the suitable effect measure and the respective
95% confidence interval (CI). The choice of a weighting
method for pooling the results of the studies will ac-
count for the rare events setting. This is because the
baseline risk for UTI is usually < 5% [9]; therefore, we
expect that studies included in the meta-analysis might
have a low number of events. Meta-analyses of studies
with rare events face challenges that should be tackled
using suitable statistical methods and proper effect mea-
sure(s) [14]. Either odds ratio (OR) or relative risk (RR)
with their respective 95% CI will be reported depending
on what authors used in the original publications. How-
ever, if we observe a high number of studies with a low
number of events and/or no events, we will use OR be-
cause in rare events settings, OR and RR are almost the
same, but OR has some computational advantages [15].
The effect measure of interest will be computed using
the metabin function of the rmeta package [14]. Forest
plot(s) will be generated to show the individual and
pooled effect measure, 95% CI, the author’s name, publi-
cation year, and study weights for primary studies.
Heterogeneity between the results of the primary stud-
ies will be assessed using the Cochran’s Q test and will
be quantified with the I-squared statistic. Assessment of
the heterogeneity form the I-square will be considered
low, moderate, or high when the values are below 25%,
between 25% and 75%, or above 75%, respectively [16].
Sources of inter-study heterogeneity will be investi-
gated with the random-effects meta-regression analysis
that will be based on the following primary study char-
acteristics: study design, publication year, the setting of
the study, and antibiotics regimen. The meta-regression
analysis will be weighted to account for both within-
study variances of treatment effects and the residual
between-study heterogeneity.
Meta-analysis will also be conducted for the secondary
outcome ABU (≥ 105 colony-forming units) using the
appropriate effect measures and the methods proposed
above.
As we do not know much about the number of events
for the outcomes (primary and secondary), we might
have to adjust the meta-analysis methods proposed
above. The analyses will be carried out using the R stat-
istical software (R version 3.4.4, R. Foundation for Statis-
tical Computing, Vienna, Austria, 2018).
For the risk factors, we will check the statistical
methods used to identify the risk factors for UTI and
will report a list of the most important risk factors for
UTI descriptively.
Meta-biases
For the results of the meta-analysis, publication bias will
be assessed using a funnel plot (a plot of effect estimates
against sample sizes). A symmetrical shape of the graph
will be interpreted as absence of publication bias,
whereas an asymmetrical shape of the graph will be
interpreted as presence of publication bias [17].
We will not assess publication bias for the exploration
of the risk factors.
Discussion
Antimicrobial resistance is particularly prevalent among
the main pathogens of the urogenital tract [18]. Patho-
gens from urological patients show high antimicrobial
resistance rates [19]. This has been explained by an
overuse and a frequently extended use of antibiotic
agents partly for AP in standard urological procedures
[20].
Thus, guidelines should ensure that the use of AP is
carefully considered and that AP is reduced to a mini-
mum without increasing the postoperative complications
for individual patients.
Bladder cancer is the most common malignancy of the
male and female urinary system [1], and TURB is the
most frequently performed procedure in diagnosis and
treatment of bladder cancer [2]. However, guideline rec-
ommendations on AP in TURB rely on outdated and
underpowered trials [8]. This leads to a low level of evi-
dence and overt discrepancies in international guideline
recommendations ranging from complete AP omission
to complete AP application for several days [7].
Moreover, the rising antimicrobial resistance rates
today impose a reasonably dosed use of AP and the care-
ful evaluation of risk factors for postoperative UTI [9].
Thus, an up-to-date systematic review with meta-
analysis may be able to provide reliable evidence to
guide decision-making on whether or not to use AP.
Furthermore, the collated knowledge on risk factors for
UTI following TURB will inform future studies to assess
which patients would benefit from AP. Such knowledge
can help to reduce the use of AP to a necessary
minimum.
Overall, carefully considered AP use may reduce the
risk for UTIs and minimize the development of
antibiotic-resistant pathogens. Furthermore, any meas-
ure to decrease antibiotic resistance rates has important
beneficial consequences for public health in general.
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Strengths and limitations
Only a systematic review and meta-analysis would be
able to provide reliable evidence to guide decision-
making on whether AP can be recommended in this set-
ting or not.
A strength of our study is the comprehensive search in
three major databases, citation chasing on included re-
cords and hand-searching of conference contributions in
order to comprehensively retrieve potentially relevant re-
cords. Limitations include the expected heterogeneity in
the sample size of the retrieved studies, quality of the
study design, rare outcome events, and definition and as-
sessment of the primary outcome. Voiding symptoms
such as dysuria or suprapubic pain can be caused by the
TURB itself and the catheterization and might not only
be a sign of UTI. Therefore, we decided to choose a
combined outcome definition of symptoms and bacteri-
uria according to the definition of the Centers for Dis-
ease Control and Prevention.
In addition to the systematic review, we would like to
get an impression of potential risk factors for UTI fol-
lowing TURB. As this investigation is merely explorative
and not intended as a systematic overview, the search is
intentionally less comprehensive as it would be for a sys-
tematic review. This means that any results shall only
serve as rationale for conducting a full systematic scop-
ing review in the future and not to inform clinical
decision-making in any kind.
Any deviations from the protocol will be outlined in
the final publication.
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